DuChemBIOLtd (A176750) Stock Overview
Engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
A176750 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
DuChemBIO Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩8,910.00 |
| 52 Week High | ₩14,950.00 |
| 52 Week Low | ₩7,070.00 |
| Beta | -0.10 |
| 1 Month Change | -10.18% |
| 3 Month Change | -11.52% |
| 1 Year Change | -30.93% |
| 3 Year Change | 63.79% |
| 5 Year Change | -1.98% |
| Change since IPO | -15.55% |
Recent News & Updates
DuChemBIOLtd's (KOSDAQ:176750) Solid Earnings May Rest On Weak Foundations
Nov 20
DuChemBIOLtd (KOSDAQ:176750) Has A Pretty Healthy Balance Sheet
May 21Investors Shouldn't Be Too Comfortable With DuChemBIOLtd's (KOSDAQ:176750) Earnings
Apr 01Shareholder Returns
| A176750 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | -2.7% | -0.5% | 1.6% |
| 1Y | -30.9% | -2.8% | 62.9% |
Return vs Industry: A176750 underperformed the KR Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: A176750 underperformed the KR Market which returned 62.9% over the past year.
Price Volatility
| A176750 volatility | |
|---|---|
| A176750 Average Weekly Movement | 4.4% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A176750 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A176750's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 115 | Sang-Woo Kim | www.duchembio.com |
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson’s disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease.
DuChemBIO Co.,Ltd. Fundamentals Summary
| A176750 fundamental statistics | |
|---|---|
| Market cap | ₩256.24b |
| Earnings (TTM) | ₩7.74b |
| Revenue (TTM) | ₩37.25b |
Is A176750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A176750 income statement (TTM) | |
|---|---|
| Revenue | ₩37.25b |
| Cost of Revenue | ₩24.22b |
| Gross Profit | ₩13.02b |
| Other Expenses | ₩5.28b |
| Earnings | ₩7.74b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 273.08 |
| Gross Margin | 34.96% |
| Net Profit Margin | 20.78% |
| Debt/Equity Ratio | 14.8% |
How did A176750 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 16:29 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
DuChemBIO Co.,Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ji-Young Kim | Kyobo Securities Co., Ltd |